EVEREST MED Shrinks 6%+ on Top-up Shr Placement at 10% Discount
Stock Performance: EVEREST MED's shares opened 5.87% lower and are currently down 6.58%, with significant trading volume of 25.401 million shares amounting to $1.779 billion.
Share Placement Announcement: The company plans to place 22.561 million shares at a price of $69.7 each, aiming to raise approximately $1.553 billion for R&D, commercialization, and working capital.
Trade with 70% Backtested Accuracy
Analyst Views on 01952
No data
About the author
<M Stanley Analysis> Ratings and Target Prices for CN Biopharma Stocks (Table)
Stock Performance: Several Hong Kong stocks experienced declines, with EVEREST MED down 2.095%, INNOVENT BIO down 1.090%, and ZAI LAB down 2.304%.
Short Selling Data: INNOVENT BIO had the highest short selling at $213.64M, with a ratio of 28.305%, indicating significant market skepticism.
Analyst Ratings: M Stanley has reinitiated coverage on INNOVENT BIO with an "Overweight" rating, suggesting potential growth in the Chinese biotech sector in the second half of 2026.
Price Targets Adjustments: Price targets for EVEREST MED and VISEN PHARMA-B were adjusted downwards, reflecting changing market conditions and expectations.
<Daily Summary> HSI Ends at 25,635, Decreasing by 183 Points; HSTI Finishes at 5,483, Down 16 Points; SANDS CHINA LTD Falls Over 4%; POWER ASSETS, SHENZHEN INT'L, CH MODERN D, GLOBAL NEW MAT Reach New Peaks; Market Turnover Increases
Market Performance: The Hang Seng Index (HSI) fell by 183 points (0.7%) to 25,635, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also experienced declines, with market turnover reaching $224.51 billion.
Active Heavyweights: Major stocks like Alibaba, Xiaomi, and Tencent saw declines, with Alibaba closing down 1.8% at $143.3, while Meituan and Ping An recorded slight gains.
Notable Movers: Sands China and JD Health faced significant drops, with Sands China down 4.5% and JD Health down 3.4%, while XPeng and BYD Company saw gains of 3.9% and 3.7%, respectively.
HSMI & HSSI Highlights: Medbot-B surged by 25.8%, while MGM China plummeted by 17.1%. Other notable movements included Minieye rising by 15.5% and Everest Med dropping by 15%.
Midday Update: HSI Ends at 25,887, Gaining 68 Points; HSTI Reaches 5,587, Up 88 Points; XPENG Surges Over 6%; JIANGXI COPPER and CH MODERN D Achieve New Highs
Market Performance: The HSI rose by 68 points (0.3%) to 25,887, while the HSTI and HSCEI also saw gains of 88 points (1.6%) and 68 points (0.8%) respectively.
Active Heavyweights: Notable stocks included MEITUAN (+2.3%), PING AN (+0.9%), and BABA (+0.3%), with significant short selling activity reported across these companies.
Top Gainers: XPENG and BYD COMPANY led the gains among HSI & HSCEI constituents, rising by 6.3% and 6% respectively, while MEDBOT-B surged by 30.4% in the HSMI & HSSI sectors.
Notable Declines: CHICMAX and MGM CHINA experienced significant drops of 14.2% and 13.5%, respectively, indicating volatility in certain sectors of the market.
<M Stanley Analysis: Ratings and Target Prices for Biotech Companies (Table)>
Stock Performance Overview: Various stocks such as VISEN PHARMA-B and AKESO show mixed performance, with VISEN PHARMA-B down by 1.138% and AKESO up by 1.002%.
Short Selling Activity: Significant short selling activity is noted across several stocks, including Zai Lab and INNOVENT BIO, with short selling ratios reaching as high as 30.955% for Zai Lab.
Analyst Ratings: Most stocks listed, including INNOVENT BIO and KEYMED BIO-B, are rated as "Outperform," indicating positive expectations from analysts.
Market Trends: The report highlights the top 10 HK stocks with the highest net buys and sells by Southbound funds, reflecting current market trends and investor interests.
EVEREST MED Shrinks 6%+ on Top-up Shr Placement at 10% Discount
Stock Performance: EVEREST MED's shares opened 5.87% lower and are currently down 6.58%, with significant trading volume of 25.401 million shares amounting to $1.779 billion.
Share Placement Announcement: The company plans to place 22.561 million shares at a price of $69.7 each, aiming to raise approximately $1.553 billion for R&D, commercialization, and working capital.
<M Stanley Analysis> Ratings and Target Prices for CN Biopharma Stocks (Table)
Stock Performance: Several Hong Kong stocks experienced declines, with EVEREST MED down 2.095%, INNOVENT BIO down 1.090%, and ZAI LAB down 2.304%.
Short Selling Data: INNOVENT BIO had the highest short selling at $213.64M, with a ratio of 28.305%, indicating significant market skepticism.
Analyst Ratings: M Stanley has reinitiated coverage on INNOVENT BIO with an "Overweight" rating, suggesting potential growth in the Chinese biotech sector in the second half of 2026.
Price Targets Adjustments: Price targets for EVEREST MED and VISEN PHARMA-B were adjusted downwards, reflecting changing market conditions and expectations.
<Daily Summary> HSI Ends at 25,635, Decreasing by 183 Points; HSTI Finishes at 5,483, Down 16 Points; SANDS CHINA LTD Falls Over 4%; POWER ASSETS, SHENZHEN INT'L, CH MODERN D, GLOBAL NEW MAT Reach New Peaks; Market Turnover Increases
Market Performance: The Hang Seng Index (HSI) fell by 183 points (0.7%) to 25,635, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also experienced declines, with market turnover reaching $224.51 billion.
Active Heavyweights: Major stocks like Alibaba, Xiaomi, and Tencent saw declines, with Alibaba closing down 1.8% at $143.3, while Meituan and Ping An recorded slight gains.
Notable Movers: Sands China and JD Health faced significant drops, with Sands China down 4.5% and JD Health down 3.4%, while XPeng and BYD Company saw gains of 3.9% and 3.7%, respectively.
HSMI & HSSI Highlights: Medbot-B surged by 25.8%, while MGM China plummeted by 17.1%. Other notable movements included Minieye rising by 15.5% and Everest Med dropping by 15%.
Midday Update: HSI Ends at 25,887, Gaining 68 Points; HSTI Reaches 5,587, Up 88 Points; XPENG Surges Over 6%; JIANGXI COPPER and CH MODERN D Achieve New Highs
Market Performance: The HSI rose by 68 points (0.3%) to 25,887, while the HSTI and HSCEI also saw gains of 88 points (1.6%) and 68 points (0.8%) respectively.
Active Heavyweights: Notable stocks included MEITUAN (+2.3%), PING AN (+0.9%), and BABA (+0.3%), with significant short selling activity reported across these companies.
Top Gainers: XPENG and BYD COMPANY led the gains among HSI & HSCEI constituents, rising by 6.3% and 6% respectively, while MEDBOT-B surged by 30.4% in the HSMI & HSSI sectors.
Notable Declines: CHICMAX and MGM CHINA experienced significant drops of 14.2% and 13.5%, respectively, indicating volatility in certain sectors of the market.
<M Stanley Analysis: Ratings and Target Prices for Biotech Companies (Table)>
Stock Performance Overview: Various stocks such as VISEN PHARMA-B and AKESO show mixed performance, with VISEN PHARMA-B down by 1.138% and AKESO up by 1.002%.
Short Selling Activity: Significant short selling activity is noted across several stocks, including Zai Lab and INNOVENT BIO, with short selling ratios reaching as high as 30.955% for Zai Lab.
Analyst Ratings: Most stocks listed, including INNOVENT BIO and KEYMED BIO-B, are rated as "Outperform," indicating positive expectations from analysts.
Market Trends: The report highlights the top 10 HK stocks with the highest net buys and sells by Southbound funds, reflecting current market trends and investor interests.
EVEREST MED Shrinks 6%+ on Top-up Shr Placement at 10% Discount
Stock Performance: EVEREST MED's shares opened 5.87% lower and are currently down 6.58%, with significant trading volume of 25.401 million shares amounting to $1.779 billion.
Share Placement Announcement: The company plans to place 22.561 million shares at a price of $69.7 each, aiming to raise approximately $1.553 billion for R&D, commercialization, and working capital.
